FDA Brief

Warning letters Drugs

FDA warning letter to

Melanie M. Hoppers, M.D./Physicians Quality Care

High riskIssued Nov 8, 2023Posted Nov 21, 2023Center for Drug Evaluation and Research | CDER

FDA warns Dr. Melanie Hoppers over enrolling ineligible patients in a baloxavir marboxil influenza trial.

What happened

FDA inspected Dr. Hoppers' clinical site between December 6 and 15, 2022, and reviewed her conduct of clinical investigations. FDA found that six subjects were randomized and given the investigational drug without the protocol-required laboratory-confirmed test result from the local study lab; some had a negative or other test result. Dr. Hoppers acknowledged the issue and blamed a clinical research coordinator, but FDA found her response inadequate on supervision, oversight, and procedures.

What FDA found

  1. The investigator did not make sure the study was conducted according to the investigational plan.

    21 CFR 312.60
  2. Six subjects were randomized and given the investigational drug without the protocol-required laboratory-confirmed test result from the local study lab.

    21 CFR 312.60
  3. For some subjects, the lab result was negative or otherwise did not meet the eligibility requirement.

    21 CFR 312.60

What FDA wants

Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations. FDA also asks for details on how the investigator will supervise study staff and documentation of additional standard operating procedures and trainings.

Who should pay attention

  • clinical trial sponsors and monitors
  • other clinical investigators and site staff
  • IRBs and site management organizations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  3. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk
  4. Prodrome Sciences USA, LLC

    Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

    High risk